PAVmed shares surge 10.43% intraday after announcing Veris Health's commercial partnership launch, implantable monitor development, and Lucid's Medicare coverage progress.

PAVmed Inc. surged 10.43% intraday following a business update and third-quarter 2025 financial report highlighting strategic advancements. Key drivers included Veris Health’s commercial partnership with The Ohio State University James Cancer Hospital and the relaunch of its implantable physiological monitor, targeting a 2026 FDA submission. Additionally, PAVmed signed a letter of intent to license groundbreaking endoscopic imaging technology from Duke University, expanding its innovation pipeline. Lucid Diagnostics reported $1.2 million in EsoGuard revenue, Medicare CAC support for coverage, and a $27 million equity raise. These developments signaled progress in commercial execution, regulatory milestones, and new growth avenues, outweighing the company’s consolidated losses and cash constraints. The market appeared to prioritize near-term operational traction and partnership expansion over near-term financial metrics, fueling the intraday rally.